CN115068666A - Anti-adhesion hemostatic hydrogel and preparation method and application thereof - Google Patents
Anti-adhesion hemostatic hydrogel and preparation method and application thereof Download PDFInfo
- Publication number
- CN115068666A CN115068666A CN202110262418.XA CN202110262418A CN115068666A CN 115068666 A CN115068666 A CN 115068666A CN 202110262418 A CN202110262418 A CN 202110262418A CN 115068666 A CN115068666 A CN 115068666A
- Authority
- CN
- China
- Prior art keywords
- adhesion
- component
- hemostatic
- hemostatic hydrogel
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 118
- 239000000017 hydrogel Substances 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 102000004190 Enzymes Human genes 0.000 claims abstract description 29
- 108090000790 Enzymes Proteins 0.000 claims abstract description 29
- 230000023597 hemostasis Effects 0.000 claims abstract description 28
- 238000004132 cross linking Methods 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims description 51
- 230000002265 prevention Effects 0.000 claims description 12
- 108060008539 Transglutaminase Proteins 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 102000003601 transglutaminase Human genes 0.000 claims description 11
- 229920002101 Chitin Polymers 0.000 claims description 7
- 239000000022 bacteriostatic agent Substances 0.000 claims description 6
- -1 CHO-PEG-CHO Chemical compound 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims description 4
- 229930195715 D-glutamine Natural products 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- VVNYDCGZZSTUBC-LURJTMIESA-N (2s)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(N)=O VVNYDCGZZSTUBC-LURJTMIESA-N 0.000 claims description 3
- JIMLDJNLXLMGLX-JTQLQIEISA-N (2s)-5-amino-5-oxo-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 JIMLDJNLXLMGLX-JTQLQIEISA-N 0.000 claims description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229960002648 alanylglutamine Drugs 0.000 claims description 3
- 108010044940 alanylglutamine Proteins 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 3
- 235000012141 vanillin Nutrition 0.000 claims description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 2
- 239000004971 Cross linker Substances 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 229940030225 antihemorrhagics Drugs 0.000 claims 2
- 230000000025 haemostatic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 abstract description 22
- 208000031737 Tissue Adhesions Diseases 0.000 abstract description 9
- 239000007787 solid Substances 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000000740 bleeding effect Effects 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 239000002262 Schiff base Substances 0.000 abstract description 2
- 150000004753 Schiff bases Chemical class 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 14
- 230000002980 postoperative effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 4
- 206010060932 Postoperative adhesion Diseases 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- LFKLPJRVSHJZPL-UHFFFAOYSA-N 1,2:7,8-diepoxyoctane Chemical compound C1OC1CCCCC1CO1 LFKLPJRVSHJZPL-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses an anti-adhesion hemostatic hydrogel and a preparation method and application thereof. The anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 5-15% of the component A, 15-25% of the component B, 0.1-5% of an enzyme cross-linking agent and the balance of water, wherein carbonyl of the component A and amino of the component B are subjected to Schiff base reaction and cross-linking to obtain the enzyme-state cross-linked hemostatic hydrogel. The anti-adhesion hemostatic hydrogel disclosed by the invention has viscoelasticity and fluidity, can be injected into tissues of a bleeding part in vitro, forms solid gel under the action of an enzyme cross-linking agent when reaching a specific temperature and tissues, quickly stops bleeding and has firm tissue adhesion, the wound after operation is quickly stopped and healed without adhesion phenomenon and inflammatory reaction, the anti-adhesion hemostatic hydrogel can bear blood pressure from blood vessels inside the wound and pressure for auxiliary hemostasis outside the wound, and the anti-adhesion hemostatic hydrogel can be widely applied to preparation of quick hemostasis and anti-adhesion products.
Description
Technical Field
The invention relates to the technical field of hemostatic materials, and in particular relates to an anti-adhesion hemostatic hydrogel and a preparation method and application thereof.
Background
Adhesions occur after 95% of invasive surgery, for example abdominal surgery, and many patients experience postoperative complications associated with adhesions, such as severe pain and/or organ dysfunction, with adhesion release being critical for postoperative adhesion prevention because 15-30% of patients require a second operation to release the adhesion.
The hydrogel is a bioactive novel functional polymer material with performance superior to that of the traditional hemostatic dressing, and can be used for hemostasis and postoperative adhesion prevention for the postoperative wound of a patient due to the characteristics of softness, high tissue water content and good tissue compatibility. However, conventional in situ hydrogel tissues have weak adhesion, fail to adhere to wet tissues, and fail to simultaneously prevent postoperative tissue adhesion, thereby severely limiting their application in repairing internal tissues. In addition, the traditional in-situ hydrogel product at present also shows some defects in structure and performance, and the most important is lower mechanical property. The hemostasis by external force is needed when the large-area hemorrhage or large-vessel hemorrhage is faced in war wounds or surgical operations, the hemostatic material used at the moment must be capable of bearing the blood pressure from the blood vessel inside the wound and the pressure of the auxiliary hemostasis outside the wound, but the mechanical strength of most in-situ hydrogels cannot meet the above conditions.
CN107261198A discloses a preparation method of an anti-seepage and anti-adhesion porous hemostatic gel dressing, which comprises the following steps: adding a composite cross-linking agent beta-diimine zinc complex, an aqueous solution of 1,2,7, 8-diepoxyoctane and an inorganic salt aqueous solution in a mass ratio of 1:3-3:1 into a mixed solution of water-soluble human-like collagen and chitosan, uniformly mixing, adjusting the pH value of the solution to 2-5.5, and placing the solution in a water bath environment for cross-linking reaction to obtain a salt-containing hydrogel; and (3) carrying out high-pressure steam treatment and distilled water soaking and washing on the crosslinked saline gel twice, removing inorganic salt and residual monomer crosslinking agent, and carrying out drying and Co-60 sterilization treatment to obtain the anti-seepage anti-adhesion porous medical hemostatic gel dressing. The hydrogel dressing prepared by the technology has a super-porous structure, high porosity, good connectivity and reasonable pore size, can quickly absorb water in blood to promote hemagglutination and realize quick hemostasis, and the surface of the hydrogel material has smaller roughness and is not easy to adhere compared with the surface of the traditional gauze or hemostatic sponge; the good connectivity of the pore passage ensures that the drug delivery is very convenient; while the smaller pore size of the material also prevents wound infection. The hemostatic gel dressing mainly aims at improving the hemostatic performance, and does not improve the hemostatic performance through optimizing the components of the hemostatic gel material and the gelling process, but improves the hemostatic performance of the material through a porous structure through structural adjustment, and does not prove that the hemostatic gel dressing also has a corresponding anti-adhesion effect.
Disclosure of Invention
The invention aims to solve the technical problems that the tissue adhesion force of the in-situ hydrogel of the prior art is weak, the in-situ hydrogel can not adhere to wet tissues and can not prevent postoperative tissue adhesion at the same time, and provides an anti-adhesion hemostatic hydrogel which is obtained by adopting a multi-response multi-component system enzyme response catalytic crosslinking, has viscoelasticity and fluidity, can form solid gel when reaching a specific temperature and tissues, and has excellent hemostatic effect and firm tissue adhesion force.
The invention also aims to provide a preparation method of the anti-adhesion hemostatic hydrogel.
Still another object of the present invention is to provide an application of the anti-adhesion hemostatic hydrogel in the preparation of a rapid hemostatic and anti-adhesion product.
It is yet another object of the present invention to provide a rapid hemostatic and anti-adhesion article.
It is a further object of the present invention to provide a system for preparing a rapid hemostatic and anti-adhesion article.
The above purpose of the invention is realized by the following technical scheme:
an anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 1-20% of component A, 10-30% of component B, 0.1-5% of enzyme cross-linking agent and the balance of water,
wherein the component A is one or more of alanylglutamine, D-glutamine, DL-glutamine, BOC-L-glutamine, N-CBZ-L-glutamine, anisaldehyde, CHO-PEG-CHO, cinnamaldehyde, vanillin, cyclodextrin aldehyde or Plutonic block copolymer;
the component B is one or more of aminated graphene, aminated gelatin, aminated polysaccharide or aminated chitin.
The hemostatic hydrogel is catalyzed and crosslinked by an enzyme crosslinking agent, and the carbonyl of the component A and the amino of the component B are subjected to Schiff base reaction crosslinking to obtain the enzyme-state crosslinked hemostatic hydrogel.
The water of the present invention may be non-deionized water.
The enzyme cross-linking agent provided by the invention not only has the function of a catalyst, but also has the effect of the cross-linking agent, and can promote catalytic cross-linking of the component A and the component B corresponding to the enzyme, so that the hemostatic hydrogel is prepared.
The hemostatic hydrogel is an enzyme-state cross-linked hemostatic hydrogel, can prevent adhesion, is prepared by adopting a bi-component system with enzyme response, has viscoelasticity and fluidity, can be injected into tissues of bleeding parts in vitro, forms solid gel when reaching a specific temperature and tissues, has a hemostatic effect, has firm tissue adhesion, can be locally retained in vivo for one month, can well heal the bleeding parts after operation, has no adhesion phenomenon and inflammatory reaction, and overcomes the product defect of the adhesion phenomenon of the conventional common hydrogel product.
In order to further optimize the hemostatic performance and anti-adhesion effect of the hemostatic hydrogel, the hemostatic hydrogel preferably comprises the following components in percentage by weight: 5-15% of the component A, 15-25% of the component B, 0.5-3% of a cross-linking agent and the balance of water.
Preferably, the enzymatic cross-linker is transglutaminase. Transglutaminase is selected as an enzyme cross-linking agent, and the A component and the B component can be better matched for catalytic cross-linking to prepare the hemostatic hydrogel product.
Further, in order to inhibit the growth and reproduction of microorganisms and bacteria and promote the healing of wounds, the hemostatic hydrogel preferably further contains a preservative and a bacteriostatic agent.
Wherein the bacteriostatic agent can be tea polyphenol bacteriostatic agent, and the preservative can be a commercially available preservative.
The invention also provides a preparation method of the anti-adhesion hemostatic hydrogel, which comprises the following steps: dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and mixing the solution S1 and the solution S2 for crosslinking reaction to form the anti-adhesion hemostatic hydrogel.
In the preparation method of the hemostatic hydrogel, the solution S1 containing the component A and the solution S2 containing the component B and the cross-linking agent are mixed and cross-linked at normal temperature, and the preparation method is convenient and rapid.
In practical application, the application of the anti-adhesion hemostatic hydrogel in preparing a rapid hemostatic and anti-adhesion product is also within the protection scope of the invention.
The hemostatic hydrogel material has excellent hemostatic performance and firm tissue adhesion, can bear blood pressure from blood vessels inside a wound and pressure for auxiliary hemostasis outside the wound, can realize rapid hemostatic healing of a postoperative wound, has no adhesion phenomenon and no inflammatory reaction, and can be widely applied to preparation of products for rapid hemostasis and adhesion prevention.
The invention also specifically protects a rapid hemostasis and adhesion prevention product prepared from the raw materials comprising the adhesion prevention hemostasis hydrogel.
In order to better apply to hemostasis and adhesion prevention of invasive surgery, the invention also protects a system for preparing the rapid hemostasis and adhesion prevention product, which comprises a syringe A and a syringe B, wherein the syringe A contains a component solution, and the syringe B contains a mixed solution of a component B and a cross-linking agent.
When the rapid hemostasis and anti-adhesion product is used, the injector A containing the S1 solution containing the component A and the injector B containing the S2 solution containing the component B and the cross-linking agent can be injected at the same time, the two components reach a hemostasis part at the same time, a solid gel can be formed at the normal body temperature (usually within the range of 10-40 ℃) of a human body or an animal, and the solid gel is adhered to tissues to achieve the effects of hemostasis and adhesion.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention provides an anti-adhesion hemostatic hydrogel which comprises a carbonyl group component A and an amino group-containing component B, has a multi-response component system, has viscoelasticity and fluidity, can be injected into tissues of bleeding parts in vitro, forms solid gel under the action of a cross-linking agent when reaching a specific temperature and tissues, and has firm tissue adhesion.
2. The anti-adhesion hemostatic hydrogel disclosed by the invention can rapidly gel when reaching the temperature and tissues of an action part, the gel time is 10-120 s, and the hemostatic performance is excellent.
3. After the anti-adhesion hemostatic hydrogel disclosed by the invention acts on a specific surgical site, a postoperative wound is rapidly hemostatic and healed, and no adhesion phenomenon and inflammatory reaction occur.
4. The anti-adhesion hemostatic hydrogel disclosed by the invention can bear blood pressure from blood vessels inside a wound and pressure for auxiliary hemostasis outside the wound, and has the tensile strength of 70-100 KPa.
5. The preparation method of the anti-adhesion hemostatic hydrogel is simple, convenient and quick.
Drawings
Fig. 1 illustrates the practical use of the hemostatic hydrogel of the present invention.
Fig. 2 is a graph of HE staining of a hemostatic hydrogel of the invention after two weeks of use.
Fig. 3 is a scanning electron micrograph of a hemostatic hydrogel of the present invention taken two weeks after use.
Fig. 4 is a picture of a hemostatic site after two weeks of use of a hemostatic hydrogel of the invention.
Fig. 5 is a photograph of a hemostatic site after one month of use of the hemostatic hydrogel of example 1 of the present invention.
FIGS. 6-9 are photographs of the hemostatic area of the hemostatic hydrogel of examples 2-5 of the present invention after two weeks of use.
Fig. 10 is a photograph of a hemostatic site two weeks after use of a hemostatic hydrogel of a comparative example of the invention.
Detailed Description
The present invention will be further described with reference to specific embodiments, but the present invention is not limited to the examples in any way. The starting reagents employed in the examples of the present invention are, unless otherwise specified, those that are conventionally purchased.
Example 1
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 10% of component A, 20% of component B, 1% of enzyme cross-linking agent and the balance of water.
Wherein the component A is D-glutamine;
the component B is aminated chitin;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 2
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 5% of component A, 25% of component B, 3% of enzyme cross-linking agent and the balance of water.
Wherein the component A is alanyl glutamine;
the component B is aminated chitin;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 3
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 15% of component A, 15% of component B, 0.5% of enzyme cross-linking agent and the balance of water.
Wherein the component A is BOC-L-glutamine;
the component B is aminated chitin;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 4
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 1 percent of component A, 10 percent of component B, 0.1 percent of enzyme cross-linking agent and the balance of water.
Wherein the component A is N-CBZ-glutamine;
the component B is aminated chitin;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 5
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 20% of component A, 30% of component B, 5% of enzyme cross-linking agent and the balance of water.
Wherein the component A is cyclodextrin aldehyde;
the component B is aminated graphene;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 6
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 10% of component A, 20% of component B, 1% of enzyme cross-linking agent and the balance of water.
Wherein the component A is vanillin;
the component B is aminated gelatin;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 7
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 10% of component A, 20% of component B, 1% of enzyme cross-linking agent and the balance of water.
Wherein, the component A is Pluronic block copolymer;
the component B is aminated polysaccharide;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 8
An anti-adhesion hemostatic hydrogel comprises the following components in percentage by weight: 10% of component A, 20% of component B, 1% of enzyme cross-linking agent and the balance of water.
Wherein, the component A is CHO-PEG-CHO;
the component B is aminated graphene;
wherein the enzyme crosslinking agent is transglutaminase.
The preparation method of the anti-adhesion hemostatic hydrogel comprises the following steps:
dissolving the component A in water to obtain a solution S1; dissolving the component B and a cross-linking agent in water to obtain a solution S2; and carrying out mixing and crosslinking reaction on the solution S1 and the solution S2 to form the anti-adhesion hemostatic hydrogel.
Example 9
A rapid hemostasis and adhesion prevention product is prepared from the adhesion prevention hemostasis hydrogel of the embodiment 1-4, and comprises an injector A and an injector B, wherein the injector A contains a component solution, and the injector B contains a mixed solution of a component B and a cross-linking agent.
The hemostatic product is applied to various hemostatic parts for postoperative hemostatic healing.
Comparative example 1
The medical hydrogel is sold in the market.
Result detection
(1) Hemostatic properties
The practical application of the rapid hemostasis and anti-adhesion product is shown in figure 1, the position of the liver at the abdomen of a rabbit is selected as an experimental part, the skin is transversely cut by a blade, an injector A containing S1 solution containing the component A and an injector B containing S2 solution containing the component B and a cross-linking agent are rapidly injected into a wound at the same time, the two components reach a hemostasis part at the same time to form solid gel, and the solid gel is adhered to tissues to play a role in hemostasis and adhesion.
The hemostatic hydrogel provided by the embodiment 1 of the invention is applied to abdominal wounds of rabbits, and can be seen to reach the wounds to form solid gel, so that the hemostasis is effectively realized.
Firstly, the gelation time of the hemostatic water is measured, and as shown in table 1, the gelation time of the hemostatic water is fast, so that the effect of fast hemostasis can be achieved.
TABLE 1 gel time test results
As can be seen from the data in the above table 1, the hemostatic water of the present invention has a short gelling time, which is within 120s, and has a significantly improved gelling time compared to the existing gelling time of 180s, and has excellent hemostatic properties.
(2) Tissue adhesion and postoperative adhesion prevention
FIG. 2 is a graph of the HE staining after two weeks of use of example 1 of the present invention, and it can be seen from FIG. 2 that the hemostatic hydrogel of the present invention is effective in hemostasis and adhesion to wounds.
FIG. 3 is a scanning electron micrograph of example 1 of the present invention taken two weeks later, and it can be seen from FIG. 3 that the two-component hydrogel had no inflammatory reaction with liver tissue two weeks later.
FIG. 4 is a photograph of a hemostatic site after two weeks of use according to example 1 of the present invention, showing that no adhesion reaction occurs at the postoperative hemostatic site after two weeks.
FIG. 5 is a photograph of a hemostatic site after one month of use of example 1 of the present invention, and it can be seen that the hydrogel remains locally in vivo and does not fall off after one month, indicating that the hemostatic hydrogel of the present invention has excellent adhesiveness.
FIGS. 6 to 9 are pictures of the hemostasis part after two weeks of use in examples 2 to 5 of the invention, and it can be seen that no adhesion reaction occurs at the postoperative hemostasis part after two weeks, and the adhesion prevention effect is good.
Fig. 10 is a photograph of the hemostatic site after application of the commercial hemostatic hydrogel of comparative example 1, from which it can be seen that significant adhesion occurred.
The hemostatic hydrogels of the examples of the present invention were subjected to gel strength measurements and the results are shown in table 2.
Table 2 gel strength test results
As can be seen from the data in the above table 2, the gel strength of the hemostatic water gel is better, is above 100KPa, has certain adhesive strength, can bear the blood pressure from the blood vessel in the wound and the pressure force for assisting in hemostasis outside the wound, and has firm tissue adhesive force.
It should be understood that the above-described embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. This need not be, nor should it be exhaustive of all embodiments. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention should be included in the protection scope of the claims of the present invention.
Claims (10)
1. An anti-adhesion hemostatic hydrogel is characterized by comprising the following components in percentage by weight: 1-20% of component A, 10-30% of component B, 0.1-5% of enzyme cross-linking agent and the balance of water,
wherein the component A is one or more of alanylglutamine, D-glutamine, DL-glutamine, BOC-L-glutamine, N-CBZ-L-glutamine, anisaldehyde, CHO-PEG-CHO, cinnamaldehyde, vanillin, cyclodextrin aldehyde or Plutonic block copolymer;
the component B is one or more of aminated graphene, aminated gelatin, aminated polysaccharide or aminated chitin.
2. The anti-adhesion hemostatic hydrogel according to claim 1, which comprises the following components in percentage by weight: 5-15% of component A, 15-25% of component B, 0.5-3% of enzyme cross-linking agent and the balance of water.
3. An anti-adhesion hemostatic hydrogel according to any one of claims 1, wherein the enzyme crosslinker is transglutaminase.
4. An anti-adhesion hemostatic hydrogel according to claim 1, wherein the component A is D-glutamine and the component B is aminated chitin.
5. An anti-adhesion hemostatic hydrogel according to claims 1 to 4, further comprising a preservative and a bacteriostatic agent.
6. The anti-adhesion hemostatic hydrogel of claim 5, wherein the bacteriostatic agent is a tea polyphenol bacteriostatic agent.
7. A method for preparing the anti-adhesion hemostatic hydrogel according to any one of claims 1 to 4, comprising the following steps: dissolving the component A in water to obtain a solution S1; dissolving the component B and an enzyme crosslinking agent in water to obtain a solution S2; and mixing the solution S1 and the solution S2 for crosslinking reaction to form the anti-adhesion hemostatic hydrogel.
8. Use of an anti-adhesion haemostatic hydrogel according to any of claims 1 to 4 in the manufacture of a rapid haemostatic and anti-adhesion product.
9. A rapid hemostatic and anti-adhesion article prepared from a starting material comprising the anti-adhesion hemostatic hydrogel of any one of claims 1 to 4.
10. A system for preparing the rapid hemostasis and adhesion prevention product of claim 9, comprising a syringe a and a syringe B, wherein the syringe a contains a solution of the component a, and the syringe B contains a mixed solution of the component B and the cross-linking agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110262418.XA CN115068666B (en) | 2021-03-10 | 2021-03-10 | Anti-adhesion hemostatic hydrogel and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110262418.XA CN115068666B (en) | 2021-03-10 | 2021-03-10 | Anti-adhesion hemostatic hydrogel and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115068666A true CN115068666A (en) | 2022-09-20 |
| CN115068666B CN115068666B (en) | 2023-12-26 |
Family
ID=83241421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110262418.XA Active CN115068666B (en) | 2021-03-10 | 2021-03-10 | Anti-adhesion hemostatic hydrogel and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068666B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0686401A2 (en) * | 1994-06-10 | 1995-12-13 | Ajinomoto Co., Inc. | Living-tissue adhesive and blood coagulant |
| US20030232746A1 (en) * | 2002-02-21 | 2003-12-18 | Encelle, Inc. | Cross-linked bioactive hydrogel matrices |
| US20040028739A1 (en) * | 2000-05-08 | 2004-02-12 | Rippon Mark Geoffrey | Wound gels |
| US20090175946A1 (en) * | 2006-07-10 | 2009-07-09 | Gelita Ag | Use of gelatin and a cross-linking agent for producing cross-linking medical glues |
| CN104208742A (en) * | 2013-05-31 | 2014-12-17 | 北京纳通科技集团有限公司 | Hemostatic crosslinked composition, its preparation method and use, and hemostatic antistick material prepared from hemostatic crosslinked composition |
-
2021
- 2021-03-10 CN CN202110262418.XA patent/CN115068666B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0686401A2 (en) * | 1994-06-10 | 1995-12-13 | Ajinomoto Co., Inc. | Living-tissue adhesive and blood coagulant |
| US20040028739A1 (en) * | 2000-05-08 | 2004-02-12 | Rippon Mark Geoffrey | Wound gels |
| US20030232746A1 (en) * | 2002-02-21 | 2003-12-18 | Encelle, Inc. | Cross-linked bioactive hydrogel matrices |
| US20090175946A1 (en) * | 2006-07-10 | 2009-07-09 | Gelita Ag | Use of gelatin and a cross-linking agent for producing cross-linking medical glues |
| CN104208742A (en) * | 2013-05-31 | 2014-12-17 | 北京纳通科技集团有限公司 | Hemostatic crosslinked composition, its preparation method and use, and hemostatic antistick material prepared from hemostatic crosslinked composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115068666B (en) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | A highly-stretchable and adhesive hydrogel for noninvasive joint wound closure driven by hydrogen bonds | |
| JP7143222B2 (en) | Mesh-based in-situ crosslinkable composition | |
| EP2233157A1 (en) | A biocompatible denatured starch sponge material | |
| CN114767919B (en) | Hydrogel powder for rapid hemostasis as well as preparation method and application thereof | |
| JP2023516335A (en) | HEMOSTATIC COVERING MATERIAL AND METHOD FOR MANUFACTURING SAME | |
| CN110732037B (en) | Hemostatic paste and preparation method thereof | |
| CN113633817A (en) | In-situ polymerization strongly-adhered antibacterial hemostatic hydrogel and preparation method and application thereof | |
| CN113663116A (en) | Ion-based hydrogel with hemostasis and adhesion resistance and preparation method and application thereof | |
| CN112870430B (en) | Composite gel hemostatic powder based on natural polysaccharide, and preparation method and application thereof | |
| CN116570757B (en) | Double-component in-situ adhesive based on super-charged protein, and preparation method and application thereof | |
| CN114848668A (en) | Composition with wound healing promoting and quick hemostasis functions | |
| CN115845122B (en) | Photosensitive and temperature-sensitive mixed high-strength hydrogel | |
| US20240238477A1 (en) | Self-adhesive absorbable biological patch and preparation method and use thereof | |
| US20240216585A1 (en) | Peg bicomponent self-adhesive absorbable biological patch and preparation method and use thereof | |
| CN115068666B (en) | Anti-adhesion hemostatic hydrogel and preparation method and application thereof | |
| CN107349464B (en) | Preparation method of novel medical hemostatic gel dressing | |
| CN112007204B (en) | Anti-infection, healing-promoting, hemostatic and anti-adhesion membrane and preparation method thereof | |
| CN112007202B (en) | Adhesive healing-promoting hemostatic sponge and preparation method thereof | |
| CN111991611B (en) | Self-repairing hemostatic sponge capable of being adhered and preparation method thereof | |
| Freundlich et al. | Bioadhesive microneedle patches for tissue sealing | |
| Ren et al. | Stimuli‐Responsive Hydrogel Adhesives for Wound Closure and Tissue Regeneration | |
| CN113350565B (en) | Medical adhesive material for vessel closure and preparation method thereof | |
| Ashrafi et al. | Engineering a mussel-inspired hemostatic sealant with a strong tissue anchor as a first-aid tissue adhesive | |
| CN111921004A (en) | Bi-component cross-linked composite material applied to urology surgery and preparation method thereof | |
| Luo et al. | In situ generation of bioadhesives using dry tannic silk particles: a wet-adhesion strategy relying on removal of hydraulic layer over wet tissues for wound care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |